Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice

Personalized therapy in endometrial cancer: Challenges and opportunities

(2012) Shannon N. Westin et al.   CANCER BIOLOGY & THERAPY

Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma

(2012) Shinichi Togami et al.   CANCER SCIENCE

Clinical significance of intratumoral HER2 heterogeneity in gastric cancer

(2012) Hee Eun Lee et al.   EUROPEAN JOURNAL OF CANCER

Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens?

(2012) Lauren T. Greer et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer

(2011) Karim S El-Sahwi et al.   Expert Review of Anticancer Therapy

Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections*

(2011) Stephen Lee et al.   HISTOPATHOLOGY

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma

(2011) Yingchuan Hu et al.   MODERN PATHOLOGY

HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population

(2011) Pamela L. Kunz et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

HER2 Testing in Gastric Cancer

(2010) Luca Albarello et al.   ADVANCES IN ANATOMIC PATHOLOGY

The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas

(2010) Aylin Gul et al.   Diagnostic Pathology

Letter to the Editor referring to the manuscript entitled: “Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study” recently reported by Fleming et al., (Gynecol Oncol., 116;15–20;2010)

(2010) Alessandro D. Santin   GYNECOLOGIC ONCOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

(2009) Gini F. Fleming et al.   GYNECOLOGIC ONCOLOGY

HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study

(2009) Mina Xu et al.   HISTOPATHOLOGY

Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenicin situhybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation

(2008) P. SINGH et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

(2008) Alessandro D. Santin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS

An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group study

(2007) T.A. Grushko et al.   GYNECOLOGIC ONCOLOGY

HER-2/neuoverexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescencein situhybridization

(2007) F.E ODICINO et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER